Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.
|Original language||American English|
|Number of pages||22|
|Journal||Allergy: European Journal of Allergy and Clinical Immunology|
|State||Published - Jun 2017|
Bibliographical noteFunding Information:
The AllergoOncology Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for their financial support in the development of this Task Force report. The authors acknowledge support by the Austrian Science Fund FWF grants P23398-B11, F4606-B28, W1205-B09, (EJJ), KLI284 (EU), P23228-B19 and P22441-B13 (DM); Israel Cancer Association #20161131 and Israel Science Foundation #472/15) (FLS); Cancer Research UK (C30122/A11527; C30122/A15774); The Academy of Medical Sciences (DHJ, SNK, JFS); the Medical Research Council (MR/L023091/1); Breast Cancer Now – the UK's largest breast cancer charity – created by the merger of Breast Cancer Campaign and Breakthrough Breast Cancer (147) (SNK); CR UK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587); and NIH/NCI grants R01CA181115 (MLP) and R21CA179680 (TRD). MCT was funded by a Canadian Institutes of Health Research Fellowship. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
- biologics, desensitization
- clinical oncology